Carvedilol recalls: lots, NDC and companies
7 FDA recall records mention Carvedilol since February 12, 2025. Each covers specific lots from one company. Check yours below.
Check your Carvedilol bottle
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories: Carvedilol Tablets USP
Hazard (FDA): CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets and 1 more
Hazard (FDA): CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets and 2 more
Hazard (FDA): CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets USP 3.125mg Tablets a.)100-count bottle and 3 more
Hazard (FDA): CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Fenofibrate Capsules 67 mg and 38 more
Hazard (FDA): CGMP Deviations
FDAMedicines
RemedyRepack Inc.: Carvedilol 25 mg Tablet
Hazard (FDA): CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets and 1 more
Hazard (FDA): CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.
FDAMedicines